Journal of American medical association study

[seahawks2884]

https://jamanetwork.com/journals/jama/f ... le/2773108
Quote: Fluvoxamine is a strong S1R agonist,10,11 is highly lipophilic, and has rapid intracellular uptake.12 This study tested whether fluvoxamine, given as early treatment in individuals with mild COVID-19 illness, may prevent clinical deterioration.

https://www.youtube.com/watch?v=gPqoFFJAaDY

Now there is some great news!

[Silverstarqueen]

The study excluded the very participants who would be most likely to have a more severe case. ?
" Exclusion criteria included having COVID-19 that required hospitalization or evidence of the primary end point with oxygen saturation less than 92% on room air at the time of randomization. Other exclusion criteria were severe underlying lung disease (eg, chronic obstructive pulmonary disease or required home oxygen, interstitial lung disease, pulmonary hypertension), decompensated cirrhosis, congestive heart failure (New York Heart Association class III or IV), or immunocompromised (eg, solid organ transplant recipient or donor, bone marrow transplant recipient, AIDS, or taking immunosuppressant biologic drugs or high-dose corticosteroids [>20 mg/d of prednisone]; additional details appear in Supplement 1"

[Fancy]

Being discussed here:
viewtopic.php?f=95&t=89208&start=5805